Claya Tirzepatide Review: Cost, Two Named Pharmacies & Honest Verdict (2026)

Claya: it names two pharmacy partners with full addresses — RedRock in Utah and Healthware in Kentucky — a genuine, checkable transparency signal rare in this category. Every fact here comes from the company's own published program.

What Claya is

Claya is a direct-to-consumer telehealth platform, offering compounded semaglutide and tirzepatide in both injectable and oral-tablet forms — a wider format range than most competitors. Claya names two licensed clinicians by name (Habashy, NMD MS and Barber, MD PhD) — rare transparency for compounded GLP-1.

What Claya costs

Tirzepatide runs $299/month. An introductory price is lower than the refill rate — by the time you reach refill, the price rises to the same $299 figure, erasing the first-month advantage. Free expedited shipping is included in the monthly price.

Two named pharmacies with addresses

This is Claya's strongest, most independently checkable claim: RedRock (Utah) and Healthware (Kentucky) are both named as pharmacy partners with full addresses — a real transparency signal most compounded sellers in this category don't offer.

The brand-vs-compounded question

Claya dispenses compounded tirzepatide, not the FDA-approved branded product. Compounded tirzepatide is pharmacy-made, not itself an FDA-approved finished drug, and was not the specific product studied in the pivotal trials — and the oral compounded tablets specifically have weaker efficacy data than injectable semaglutide. See our guide to whether compounded tirzepatide is still legal in 2026 for the regulatory picture.

How the care model holds up

Claya's real strengths: two named pharmacy partners with full addresses, both injectable and oral-tablet forms, and two named licensed clinicians, a published money-back guarantee, and free expedited shipping included in the price. The trade-offs: the states-served list isn't disclosed — you must check at checkout — LegitScript certification status isn't displayed, the corporate legal entity isn't disclosed, oral tablets have weaker efficacy data than injectables, and the intro price rises to match the $299 refill rate, erasing the first-month advantage. As with any GLP-1 program, confirm your state's coverage at checkout before committing; tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Judge the provider on price, oversight and disclosure; judge the molecule on its trials. Tirzepatide's are strong — roughly 15–21% of body weight over 72 weeks in SURMOUNT-1¹, and better than semaglutide head-to-head² — but they were run on the brand drug at FDA-approved doses. Our tirzepatide evidence guide has the full picture.

The honest verdict

Claya's two named pharmacies and clinicians are genuine, checkable strengths this review and the oral-tablet option is a real format choice most competitors skip. Just budget for the $299 refill rate from month one, since the intro price doesn't hold. If named pharmacies with an oral option matter to you, compare it against BetterMe Rx, which also offers oral tablets; for a genuinely flat rate that doesn't step up at refill, see CoreAge Rx. For another provider that names its clinical partner directly, see Coivas. And for another genuine oral, needle-free option, see Dr. Arevitalize. See our best tirzepatide providers ranking for the full field.